1 completed, 1 recruiting. 1 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Subclinical Cushing's: new trials by email Literature Review of Subclinical Cushing's trials Research Report on Subclinical Cushing's
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion Intervention 1: Adrenalectomy, Intervention 2: Semaglutide - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Not applicable | Recruiting | University of Texas Southwestern Medical Center | 75 | 2026-03-05 | 2026-03-27 |
| Glucocorticoid Receptor Antagonism in Subclinical Cushings Mifepristone - Subclinical Cushing's | Phase 1 / Phase 2 | Completed | Sheffield Teaching Hospitals NHS Foundation Trust | 6 | 2008-11-01 | 2021-01-26 |
ACTH Syndrome, Ectopic (1) · Adrenal incidentaloma (1) · Cushing Syndrome (1) · Insulin Resistance (1) · Weight Loss (1)
Adrenal Gland Diseases (1) · Adrenocortical Hyperfunction (1) · Body Weight (1) · Body Weight Changes (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Hyperinsulinism (1) · Metabolic Diseases (1) · Neoplasms (1) · Nutritional and Metabolic Diseases (1) · Paraneoplastic Endocrine Syndromes (1) · Paraneoplastic Syndromes (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Mifepristone (1)
Sheffield Teaching Hospitals NHS Foundation Trust (1) · University of Texas Southwestern Medical Center (1)
United Kingdom (1) · United States (1)
K23DK142038 (1)